Diarrhea News and Research

Latest Diarrhea News and Research

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine.

21 Jan 2016

Mayo Clinic adds robots to prevent C-diff bacteria

Mayo Clinic has added robots in its fight against Clostridium difficile (C-diff) bacteria. In the U.S., C-diff is one of the most common infections patients can get while receiving care at a health care facility. C-diff can cause a variety of symptoms, including potentially deadly diarrhea. A recent national report shows some progress in reducing C-diff infections; however, more work remains.

20 Jan 2016

Frozen fecal transplantation effective at providing relief to C. diff patients

Frozen fecal transplantation is effective at providing relief to Clostridium difficile (C. diff) patients, according to a new study co-authored by University of Guelph researchers.

18 Jan 2016

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

The cancer drug paclitaxel just got more effective. For the first time, researchers from the University of North Carolina at Chapel Hill have packaged it in containers derived from a patient's own immune system, protecting the drug from being destroyed by the body's own defenses and bringing the entire payload to the tumor.

18 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

Simple paper test could confirm presence of illnesses even before patients feel symptoms

A multi-disciplinary team of researchers has developed a new diagnostic test that can change the medical landscape by making it possible for patients to quickly determine if they are infected with an illness, using a simple paper test sensitive enough to detect markers of various illnesses using minute amounts of blood, sweat, or other biological material.

13 Jan 2016

Researcher seeks to identify probiotic mixes to treat Clostridium difficile infections

Antibiotics that fight infection can adversely affect the digestive tract and give destructive bacteria a chance to flourish, said assistant professor of veterinary and biomedical sciences Joy Scaria of South Dakota State University. His research seeks to identify probiotic mixes to treat intestinal infections, such as Clostridium difficile.

12 Jan 2016

Discoveries could lead to development of novel therapies to prevent C. diff infection

Researchers at Vanderbilt University Medical Center have obtained the crystal structure of a toxin from the bacterium Clostridium difficile ("C. diff") -- the leading cause of hospital-acquired diarrhea in the United States.

12 Jan 2016

Ebola health-care workers develop guidelines for treating children during future outbreaks

When the Ebola virus outbreak erupted in West Africa in 2014, children infected with the virus -- particularly those under age 5 -- faced overwhelming challenges. Not only was there a high death rate among young children infected with the disease, they often were isolated from their families, leaving them feeling distressed and without the intensive care they needed.

8 Jan 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer announced today that new research findings on Xofigo (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place January 7 – 9 in San Francisco.

4 Jan 2016

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology.

30 Dec 2015

Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

For some time doctors have known that psychological therapies can reduce the symptoms of irritable bowel syndrome in the short term.

29 Dec 2015

Selexipag holds promise for treatment of pulmonary hypertension

Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine.

24 Dec 2015

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

Cannabidiol (CBD), a medical marijuana derivative, was effective in reducing seizure frequency and well-tolerated and safe for most children and young adults enrolled in a year-long study led by epilepsy specialists at NYU Langone Medical Center.

24 Dec 2015

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

22 Dec 2015

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

22 Dec 2015

New funding supports research on new and improved drug treatments for tuberculosis, malaria

University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases -- thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation.

17 Dec 2015

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.

12 Dec 2015

Diarrhea News and Research

Latest Diarrhea News and Research

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Mayo Clinic adds robots to prevent C-diff bacteria

Frozen fecal transplantation effective at providing relief to C. diff patients

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Simple paper test could confirm presence of illnesses even before patients feel symptoms

Researcher seeks to identify probiotic mixes to treat Clostridium difficile infections

Discoveries could lead to development of novel therapies to prevent C. diff infection

Ebola health-care workers develop guidelines for treating children during future outbreaks

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

New oral breast cancer drug has potential to combat other types of cancer

Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

Selexipag holds promise for treatment of pulmonary hypertension

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

New funding supports research on new and improved drug treatments for tuberculosis, malaria

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in